期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
Exploration on Ideological and Political Teaching of Urban Garden Green Space Planning
1
作者 Shuang LIU Yudan SUN +2 位作者 Zhixian ZOU Lusen ZHANG tingfeng huang 《Asian Agricultural Research》 2022年第11期80-82,共3页
Curriculum ideological and political teaching is an important way to realize the fundamental task of strengthening moral education and cultivating people in today's colleges and universities.Urban Garden Green Spa... Curriculum ideological and political teaching is an important way to realize the fundamental task of strengthening moral education and cultivating people in today's colleges and universities.Urban Garden Green Space Planning is one of core courses of landscape major.In this paper,taking the ideological and political construction of the course as an opportunity,starting from the course characteristics,the ideological and political elements contained in the course were excavated and refined,and their connotations were integrated into the theoretical teaching and practical training process.During imparting knowledge,the ideological and political awareness and professional quality of students can be improved,so as to achieve the educational goal of strengthening moral education and cultivating people,and provides reference for the teaching reform of integrating ideological and political education into other landscape courses. 展开更多
关键词 Curriculum ideological and political education Landscape design Teaching reform
在线阅读 下载PDF
肝内胆管细胞癌术后极早期复发的危险因素
2
作者 余承澍 刘红枝 +15 位作者 林科灿 林起柱 黄霆峰 周伟平 程张军 楼健颖 郑树国 毕新宇 王剑明 郭伟 李富宇 王坚 郑亚民 李敬东 程石 曾永毅 《中华肝脏外科手术学电子杂志》 2025年第1期53-59,共7页
目的探讨肝内胆管细胞癌(ICC)患者术后极早期复发(VER)的危险因素。方法回顾性分析2011年12月至2017年12月于福建医科大学孟超肝胆医院、海军军医大学东方肝胆外科医院、东南大学附属中大医院、浙江大学医学院附属第二医院、陆军军医大... 目的探讨肝内胆管细胞癌(ICC)患者术后极早期复发(VER)的危险因素。方法回顾性分析2011年12月至2017年12月于福建医科大学孟超肝胆医院、海军军医大学东方肝胆外科医院、东南大学附属中大医院、浙江大学医学院附属第二医院、陆军军医大学第一附属医院、中国医学科学院北京协和医学院肿瘤医院、华中科技大学同济医学院附属同济医院、首都医科大学附属北京友谊医院、四川大学华西医院、上海交通大学医学院附属仁济医院、首都医科大学宣武医院、川北医学院附属医院、首都医科大学附属天坛医院13家中心接受手术治疗的445例ICC患者临床资料。患者均签署知情同意书,符合医学伦理学规定。其中男270例,女175例;年龄23~88岁,中位年龄57岁。肿瘤直径1.1~20.4 cm,中位直径6.0 cm。以术后6个月内发生ICC复发为标准分为VER组(328例)和非VER组(117例)。采用Logistic单因素和多因素回归分析术后随访资料,生存分析采用Kaplan-Meier法和Log-rank检验。结果Logistic多因素回归分析显示,性别(OR=0.51,95%CI:0.32~0.84)、年龄(OR=0.97,95%CI:0.95~0.99)、肿瘤数目(OR=1.28,95%CI:1.06~1.54)、病理类型(OR=0.40,95%CI:0.16~0.99)、肿瘤最大径(OR=1.10,95%CI:1.02~1.17)是ICC术后患者VER的独立影响因素(P<0.05)。随访6~73个月,中位随访时间21个月。随访期间236例死亡,209例存活。VER组和非VER组术后1、3、5年生存率分别为60.71%、7.14%、0和89.90%、54.40%、25.30%,差异有统计学意义(χ^(2)=88.844,P<0.001)。结论病理类型、肿瘤数目、肿瘤最大径等为ICC术后VER的独立影响因素,VER患者生存预后较差。 展开更多
关键词 肝内胆管细胞癌 肝肿瘤 复发 极早期 危险因素
原文传递
Tumor burden score and alpha-fetoprotein level predict prognosis of patients with unresectable hepatocellular carcinoma treated with tyrosine kinase inhibitor and anti-PD-1 antibody
3
作者 Shichuan Tang tingfeng huang +9 位作者 Cong Luo Jun Fu Kailing Zhang Qingjing Chen Jie Kong Jianxi Zhang Zhenghong Sun Yongkang Diao Kongying Lin Yongyi Zeng 《iLIVER》 2024年第3期22-31,共10页
Background:Tyrosine kinase inhibitors(TKIs)and anti-PD-1 antibodies in combination provide survival benefits for patients with unresectable hepatocellular carcinoma(uHCC).However,the tool used to determine which patie... Background:Tyrosine kinase inhibitors(TKIs)and anti-PD-1 antibodies in combination provide survival benefits for patients with unresectable hepatocellular carcinoma(uHCC).However,the tool used to determine which patients likely benefit most from this treatment strategy has not been reported.We sought to develop a prognostic scoring system based on tumor burden score(TBS)and alpha-fetoprotein(AFP)to predict the long-term prognosis of uHCC treated with TKIs and anti-PD-1 antibodies.Methods:Data on patients with uHCC treated with TKIs and anti-PD-1 antibodies from multiple centers were collected.The prognostic accuracy of TBS,AFP,Barcelona Clinic Liver Cancer(BCLC),and CTA(Combined TBS and AFP)for 2-year progression-free survival(PFS)and overall survival(OS)was evaluated.Results:Overall,278 patients with uHCC treated with TKIs and anti-PD-1 antibodies were enrolled,including 48 BCLC-B and 230 BCLC-C HCC patients.CTA(AUC?0.721 and 0.683)outperformed TBS(AUC?0.680 and 0.621),AFP(AUC?0.606 and 0.594),and BCLC staging(AUC?0.551 and 0.555)in predicting PFS and OS.The 2-year PFS and OS for low CTA(low TBS/low AFP)were 65.7%and 94.4%,respectively,which were significantly higher than 21.6%and 44.9%(p<0.001 and p?0.002),respectively,for intermediate CTA(low TBS/high AFP or high TBS/low AFP)and 8.7%and 12.1%(both p<0.001),respectively,for high CTA(high TBS/high AFP).Multivariable Cox regression analysis indicated that CTA grading was an independent prognostic factor for PFS and OS(referent:low CTA;intermediate CTA,HR 2.87 and 7.17;high CTA,HR 5.52 and 10.31,respectively).Conclusions:CTA grading is an accurate tool for stratifying the prognosis of uHCC treated with TKIs and anti-PD-1 antibodies and may help determine which patients may benefit more from this treatment strategy. 展开更多
关键词 Hepatocellular carcinoma Tyrosine kinase inhibitor Anti-PD-1 antibody Tumor burden score ALPHA-FETOPROTEIN
原文传递
Immunotherapy versus lenvatinib in advanced hepatocellular carcinoma:The critical role of subgroup analyses
4
作者 tingfeng huang Jia-Hao Law +1 位作者 Ningqi Pang Shichuan Tang 《iLIVER》 2025年第4期290-291,共2页
Dear Editor,Hepatocellular carcinoma(HCC)is highly aggressive and ranks among the leading causes of cancer-related deaths worldwide.The evaluation of treatment options and outcomes for patients with advanced HCC remai... Dear Editor,Hepatocellular carcinoma(HCC)is highly aggressive and ranks among the leading causes of cancer-related deaths worldwide.The evaluation of treatment options and outcomes for patients with advanced HCC remains a major focus in both clinical practice and research.Significant progress has been made in the treatment of advanced HCC with the introduction of various systemic therapies,including lenvatinib and regimens based on immune checkpoint inhibitors.However,a critical question remains:How to compare the relative effectiveness of immunotherapy versus multi-target tyrosine kinase inhibitors in real-world populations,thereby providing evidence for personalized first-line treatment decisions across different etiologies and patient subgroups. 展开更多
关键词 evaluation treatment options outcomes systemic therapiesincluding subgroup analyses immunotherapy advanced hepatocellular carcinoma lenvatinib
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部